Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) has announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. A rare population malignancy is a subpopulation within a higher incident disease population (e.g. BRCA 1 and 2 breast cancer). These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies.

As part of the I-O RPM program, Bristol-Myers Squibb, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) are pleased to announce that they have entered into a collaboration agreement. The Lurie Cancer Center and NMDTI will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within the NMDTI Developmental Therapeutics Fellowship program.

"Complementing our broad research and development programs through innovative collaborations with partners such as the Lurie Cancer Center and NMDTI has been a fundamental component to our commitment to leading advances in Immuno-Oncology," said Laura Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb. "Cooperation between industry and research partners of this caliber offers a tremendous opportunity to further strengthen our scientific and clinical understanding of the role immunotherapies can play in the treatment of a broad range of cancers."

"Immunotherapy is rapidly evolving and has an enormous promise for cancer patients. This collaborative effort with Bristol-Myers Squibb will further strengthen our efforts to develop innovative new therapies against a wide variety of malignancies," said Leonidas C. Platanias, M.D., Ph.D., director of the Lurie Cancer Center.

"The Rare Population Malignancy Program is a very timely and important initiative. The ability to rapidly investigate the clinical utility of Bristol-Myers Squibb's Immuno-Oncology agents, as single agents or in combinations, including with therapies from other sources, is a powerful accelerant to our programs. The focus on malignancies that are otherwise relatively under-investigated in therapeutic terms is particularly important and satisfying for all involved in this collaboration," said Francis J. Giles, M.D., director of the NMDTI and deputy director of the Lurie Cancer Center.

Immuno-Oncology is an innovative approach to cancer research and treatment that is designed to harness the body's own immune system to fight cancer. The I-O RPM program will focus on significant areas of high unmet need marked by poor outcomes among patients with these cancers. Existing clinical research, including studies being conducted by the Lurie Cancer Center and NMDTI, provide a strong rationale for further research into the potential of immunotherapies for these cancers.

About Bristol Myers Squibb
The I-O RPM builds on Bristol-Myers Squibb's formation in 2012 of the International Immuno-Oncology Network (II-ON). II-ON is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is one of only 45 National Cancer Institute (NCI)-designated "Comprehensive" cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer and part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities. The Lurie Cancer Center is affiliated with four leading teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children's Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran's Affairs Medical Center, treating more than 10,000 new patients with cancer each year. The Lurie Cancer Center receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA060553).

About the Northwestern Medicine Developmental Therapeutics Institute
The Northwestern Medicine Developmental Therapeutics Institute (NMDTI) provides infrastructure and expertise to accelerate the developmental therapeutics process. With dedicated patient care facilities, experienced physician-scientists, and specialized advanced practice providers, pharmacists, and allied staff, NMDTI brings a large external pipeline of investigational agents to our patients while accelerating the development of Northwestern University's internal pipeline of novel therapies. The NMDTI Developmental Therapeutics Fellowship, supported by the Woman's Board of Northwestern Memorial Hospital, focuses on nurturing physician scientists whose career is dedicated to the development of novel approaches to curing cancer.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]